Quantcast

Latest Epigenomics AG Stories

2013-09-29 23:01:19

The report “Biomarkers Market – ([Discovery Technologies - Proteomics, Genomics, Imaging, Bioinformatics], Validation Services, Applications [drug development, personalized medicine], Diseases [Oncology, Cardiology, Neurology]) – Global Trends & Forecasts (2013 – 2018)” says global biomarkers market shows a high growth potential and accounts for $17.5 billion in 2013. Dallas, Texas (PRWEB) September 29, 2013 A biomarker is an identifiable and measurable characteristic, which...

2013-06-13 23:27:32

RiboMed Biotechnologies, Inc. (http://www.ribomed.com), a company that develops epigenetic-based tests that provide improved cancer diagnosis and allow drug therapy to be personalized for the benefit of cancer patients, today announced that it has partnered with researchers at the Austrian Institute of Technology (AIT, Vienna) to commercialize their clinically validated lung cancer DNA methylation biomarkers. Lung cancer is the number-one cause of cancer deaths in both men and women in the...

2013-01-10 05:01:24

Leading National Reference Laboratory Services Provider, ARUP Laboratories, Introduces Blood Test to Aid in the Early Detection of Lung Cancer. Innovative Blood Test will assist Clinicians in Identifying Deadly Disease Earlier Salt Lake City, UT (PRWEB) January 09, 2013 ARUP Laboratories announced today that it is entering into an agreement with Kansas-based Oncimmune® USA LLC to offer EarlyCDT®-Lung, the blood test that aids in the risk assessment and the early detection of lung...

2010-01-11 09:15:00

MADISON, N.J., Jan. 11 /PRNewswire-FirstCall/ -- A new blood test that identifies changes in DNA associated with colorectal cancer is now available in the U.S. through Quest Diagnostics Incorporated (NYSE: DGX), the world's leading cancer diagnostics company. The test is designed to aid the detection of colorectal cancer, the third leading cause of cancer-related deaths. The new test is based on DNA methylation of the Septin9 gene, a proprietary biomarker associated with colorectal cancer...

2008-10-27 06:00:09

-- Successfully qualified 17 PRESEPT clinical sites; 12 sites initiated -- Enrollment nearly 500 hundred subjects in first three months -- Expanded clinical site network to include first site in Germany -- Launched PRESEPT Study website found at www.presept.net -- Added Prof. Dr. Thomas Rosch to the Clinical Study Steering Committee -- Appointed Dr. Timothy R. Church responsible for study results analysis -- Clinical Study Steering Committee recommends...

2008-10-16 03:00:08

BERLIN and SEATTLE, Oct. 16, 2008 (GLOBE NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX) (Prime Standard), a cancer molecular diagnostics company developing tests based on DNA methylation, today reported positive final results from its prognostic prostate cancer study. "After testing all patient samples for methylation in the PITX2 gene we have successfully conducted our final analysis," commented Dr. Gunter Weiss, Vice President Product Development at Epigenomics. "This analysis shows that...

2008-09-08 03:00:06

-- Clinical study of over 500 patient samples well on track for completion in Q4 2008 -- Interim analysis representing approximately half of the cases demonstrates statistical significance for primary endpoint of prostate cancer prognosis (probability of recurrence) -- PITX2 biomarker classifies patients into groups at high and low risk for relapse following surgery BERLIN, and SEATTLE, Sept. 8, 2008 (GLOBE NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX) (Prime...

2008-07-29 03:00:00

BERLIN and SEATTLE, July 29, 2008 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt Prime Standard:ECX), a molecular diagnostics company focusing on the development and commercialization of products for cancer detection based on DNA methylation, today announced that it received a Rule 71(3) notification stating that the European Patent Office intends to grant a patent for Epigenomics' Septin 9 biomarker. This notification is equivalent to a "Notice of Allowance" by the United States Patent and...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related